Core Insights - Compass Therapeutics, Inc. is presenting its preclinical development of CTX-10726, a bispecific antibody targeting PD-1 and VEGF-A, at the 40th Society for Immunotherapy of Cancer Annual Meeting [1][3] Company Overview - Compass Therapeutics is a clinical-stage biopharmaceutical company focused on oncology, developing proprietary antibody-based therapeutics to treat various human diseases [4][7] - The company emphasizes the interplay between angiogenesis, the immune system, and tumor growth, aiming to create a robust pipeline of product candidates targeting critical biological pathways for effective anti-tumor responses [4][7] Product Development - CTX-10726 is designed for patients with metastatic or locally advanced tumors, enhancing anti-tumor responses by targeting both immune checkpoints and tumor vasculature [3][5] - The bispecific antibody has shown potent anti-tumor activity in preclinical mouse models, outperforming competitive antibodies like ivonescimab in controlling tumor growth [5][6] - IND submission for CTX-10726 is on track for Q4 2025 [5] Preclinical Data Highlights - In vitro, CTX-10726 demonstrated high-affinity binding to VEGF-A and PD-1, effectively blocking their interactions in a dose-dependent manner [6] - In vivo studies showed superior anti-tumor efficacy in various cancer models, including human lung and colon cancer, with significant tumor size reduction compared to other treatments [6]

Core Viewpoint - SITE Centers Corp. announced the sale of Parker Pavilions for approximately $8.4 million, with part of the proceeds used to repay $6.1 million of mortgage debt [1]. Group 1: Company Overview - SITE Centers Corp. is an owner and manager of open-air shopping centers and operates as a self-administered and self-managed REIT [2][5]. - The company is publicly traded on the New York Stock Exchange under the ticker symbol SITC [2]. Group 2: Recent Transactions - The sale of Parker Pavilions was completed prior to closing costs, prorations, and other adjustments [1]. - The company has also announced a special cash distribution of $1.00 per common share, payable on November 14, 2025, to shareholders of record at the close of business on October 31, 2025 [4][5].

Core Insights - U.S. stock futures showed a mostly positive trend, with Nasdaq futures increasing by over 1% on Friday [1] - Roku Inc experienced a significant decline in pre-market trading following its third-quarter earnings report [1] Company Performance - Roku reported third-quarter net revenue of $1.211 billion, reflecting a 14% year-over-year increase, surpassing the Street consensus estimate of $1.206 billion [2] - The platform revenue for Roku was $1.06 billion, up 17% year-over-year, while device revenue decreased by 5% to $146 million [2] - Roku shares fell by 5% to $94.99 in pre-market trading following the earnings report [2] Other Companies in Focus - SPS Commerce Inc saw a 32.1% drop in shares to $70.57 after mixed third-quarter results and lower fourth-quarter guidance [4] - Corbus Pharmaceuticals Holdings Inc's shares fell 16.4% to $13.74 due to a public offering announcement [4] - Onespan Inc's shares decreased by 16.1% to $13.02 after reporting disappointing third-quarter sales and lowering FY25 guidance [4] - Savers Value Village Inc's shares dipped 15% to $11.25 following worse-than-expected third-quarter sales and lowered FY25 GAAP EPS guidance [4] - GSI Technology, Inc. shares fell 14.1% to $9.50 after second-quarter results [4] - Newell Brands Inc's shares declined 13.1% to $4.10 due to downbeat third-quarter results and lowered FY25 guidance [4] - DexCom Inc's shares fell 12.1% to $59.97 after announcing third-quarter results [4] - Site Centers Corp's shares declined 11.2% to $7.44 ahead of its third-quarter earnings release [4] - Aptiv PLC shares fell 7.6% to $75.88 [4] - Ventas Inc shares declined 7.5% to $68.77 [4] - Cooper-Standard Holdings Inc's shares fell 6.3% to $33.52 after reporting disappointing third-quarter results and lowering FY25 sales guidance [4]

Core Insights - U.S. stock futures showed a mostly positive trend, with Nasdaq futures increasing by over 1% on Friday [1] - Roku Inc experienced a significant decline in pre-market trading following its third-quarter earnings report [1] Company Performance - Roku reported third-quarter net revenue of $1.211 billion, reflecting a 14% year-over-year increase, surpassing the Street consensus estimate of $1.206 billion [2] - The company's platform revenue reached $1.06 billion, up 17% year-over-year, while devices revenue fell to $146 million, down 5% year-over-year [2] - Roku shares dropped 5% to $94.99 in pre-market trading following the earnings announcement [2] Other Company Movements - SPS Commerce Inc saw a 32.1% decline in pre-market trading to $70.57 after mixed third-quarter results and lower fourth-quarter guidance [4] - Corbus Pharmaceuticals Holdings Inc's shares fell 16.4% to $13.74 due to a public offering announcement [4] - Onespan Inc's shares decreased by 16.1% to $13.02 after reporting disappointing third-quarter sales and lowering FY25 guidance [4] - Savers Value Village Inc's shares dipped 15% to $11.25 following worse-than-expected third-quarter sales and lowered FY25 GAAP EPS guidance [4] - GSI Technology, Inc. shares fell 14.1% to $9.50 after second-quarter results [4] - Newell Brands Inc's shares declined 13.1% to $4.10 due to downbeat third-quarter results and lowered FY25 guidance [4] - DexCom Inc's shares dropped 12.1% to $59.97 after announcing third-quarter results [4] - Site Centers Corp's shares declined 11.2% to $7.44 ahead of its third-quarter earnings release [4] - Aptiv PLC and Ventas Inc saw declines of 7.6% to $75.88 and 7.5% to $68.77, respectively [4] - Cooper-Standard Holdings Inc's shares fell 6.3% to $33.52 after reporting disappointing third-quarter results and lowering FY25 sales guidance [4]

Core Viewpoint - SITE Centers Corp. announced a special cash distribution of $1.00 per common share, payable on November 14, 2025, to shareholders of record as of October 31, 2025 [1] Company Overview - SITE Centers Corp. is an owner and manager of open-air shopping centers [1] - The company operates as a self-administered and self-managed Real Estate Investment Trust (REIT), functioning as a fully integrated real estate company [1]

Core Insights - Aptevo Therapeutics is actively participating in several key financial, industry, scientific, and medical conferences this fall to showcase its ongoing developments and momentum in the biotechnology sector [1] Conference Participation - Aptevo will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, discussing its lead asset mipletamig and its clinical progress in Acute Myeloid Leukemia (AML) [1] - The company will also be present at the Biotechnology Innovation Organization (BIO)-Europe 2025 from November 3-5, 2025, engaging in meetings at the largest biotechnology event in Europe [1] - At the Society of Immunotherapy in Cancer (SITC) 2025, scheduled for November 5-9, 2025, Aptevo's R&D team will present a poster on a novel trispecific targeting approach to address the immunosuppressive tumor microenvironment [1] - The interim results from the ongoing Phase 1b/2 RAINIER trial evaluating mipletamig in frontline combination therapy for AML will be presented at the American Society of Hematology (ASH) 2025 meeting from December 6-9, 2025 [1]

Core Insights - Context Therapeutics Inc. is advancing T cell engaging bispecific antibodies for solid tumors and will present two posters at the Society for Immunotherapy of Cancer's 40th Annual Meeting in November 2025 [1][2] Presentation Details - The first poster is titled "Trial in Progress: A Phase 1, First-in-Human Study of CT-95, a mesothelin (MSLN)-Directed Bispecific T Cell engager (TCE) in Subjects with Advanced Solid Tumors," scheduled for November 8, 2025, at 10:00 AM ET [3] - The second poster is titled "CT-202: a dual pH-dependent Nectin-4 x CD3 bispecific T cell engager," scheduled for November 7, 2025, at 10:00 AM ET [3] Product Information - CT-95 targets mesothelin, a protein overexpressed in approximately 30% of cancers, and is designed to minimize the impact of shed MSLN that can interfere with treatment [4] - CT-202 targets Nectin-4, which is overexpressed in various solid tumors, and is designed to be preferentially active within the tumor microenvironment [5] Company Overview - Context Therapeutics is headquartered in Philadelphia and is focused on developing a portfolio of TCE bispecific therapeutics, including CTIM-76, CT-95, and CT-202 [6]

Core Insights - Xilio Therapeutics, Inc. is set to present multiple clinical and preclinical data at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting from November 6-9, 2025, focusing on tumor-activated immuno-oncology therapies for cancer patients [1][2]. Company Overview - Xilio Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing tumor-activated immuno-oncology therapies aimed at improving patient outcomes while minimizing systemic side effects associated with current treatments [2]. Upcoming Presentations - The company will present clinical data for vilastobart, an anti-CTLA-4 therapy, and efarindodekin alfa (XTX301), an IL-12 therapy, along with preclinical data on masked T cell engager programs [2]. - Specific poster presentations include: - "ctDNA as a Potential Surrogate Biomarker for Response to Combination Vilastobart and Atezolizumab in Heavily Pretreated Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)" on November 7, 2025 [4]. - "XTX301, a Tumor-Activated Interleukin-12 (IL-12), Demonstrated IL-12 Pharmacology in Patients with Advanced Solid Tumors: Pharmacodynamic Data from First-in-Human Phase 1 Study" on November 7, 2025 [4]. - "Masked T Cell Engagers Designed to Drive Potent Synthetic Anti-Tumor Immunity with Favorable Tolerability" on November 8, 2025 [4].

Core Insights - Werewolf Therapeutics, Inc. is set to present three posters at the Society for Immunotherapy of Cancer's 40th Annual Meeting, highlighting its innovative biopharmaceutical developments aimed at stimulating the immune system for cancer treatment [1][2]. Group 1: Poster Presentations - The first poster will discuss the sequential administration of WTX-124 and mWTX-330, showcasing enhanced antitumor activity in mice with poorly immunogenic EMT6 tumors without systemic toxicity [2]. - The second poster will focus on the development of conditional T cell engagers (INDUCER™ molecules) that utilize a masking approach to minimize dose-limiting cytokine release and off-target toxicity [2]. - The third poster will provide pharmacokinetic insights into the IL-2 INDUKINE prodrug WTX-124, emphasizing real-time assessment of tumor-specific activation and immune modulation [2]. Group 2: Company Overview - Werewolf Therapeutics is pioneering the development of therapeutics designed to stimulate the immune system for treating cancer and other immune-mediated conditions, leveraging its proprietary PREDATOR® platform [3]. - The company is advancing its most clinical-stage product candidates, WTX-124 and WTX-330, which are conditionally activated Interleukin-2 and Interleukin-12 INDUKINE molecules, respectively, for solid tumor treatment [3]. - Werewolf is also developing INDUCER molecules, with the first candidate, WTX-1011, targeting STEAP1 for prostate cancer, building on positive data from its INDUKINE molecules [3].

Site Centers (SITC 1.89%), a major U.S. operator of open-air shopping centers, released its earnings for the second quarter on August 5, 2025. The most notable headline is that Non-GAAP (Operating FFO) per share was $0.16 in Q2 2025 -- a figure that beat the consensus estimate of $(0.16) non-GAAP EPS. This marks a sharp outperformance versus expectations, as non-GAAP EPS of $0.16 exceeded the analyst estimate of -$0.16, but reflects a much smaller business following the spin-off of Curbline Properties and m ...